One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Oragenics logo
Oragenics OGEN
$ 0.35 0.0%
report update icon

Quarterly report 2026-Q2
added 08-13-2026

Oragenics Financial Statements 2025-2009 | OGEN

Annual Financial Statements Oragenics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Market Cap

1.73 M 177 K 3.24 M 6.55 M 816 K - 18.6 M 12 M 11.4 M 30.3 M 37.8 M 28.6 M 107 M 57.6 M 7.15 M 1.08 T -

Shares

2.16 M 221 K 2.25 M 2.01 M 1.94 M 56.5 M 42.3 M 13 M 4.93 M 4.46 M 3.67 M 3.62 M 2.88 M 1.77 M 572 K 5.66 M -

Historical Prices

0.8 0.8 1.44 3.26 0.42 0.92 0.44 0.93 2.18 7 10.3 7.9 37.4 32 12 191 K 36 K

Net Income

-984 K -1.06 M -20.7 M -14.3 M -15.7 M -26.4 M -15.6 M -9.91 M -6.73 M -7.01 M -11.7 M -5.79 M -16.1 M -13.1 M -7.68 M -7.81 M -

Revenue

- - 37.7 K 132 K 87 K - - - - - 1.18 M 940 K 1.03 M 1.33 M 1.44 M 1.31 M -

Gross Profit

- - - - - - - - - - 694 K 570 K 689 K 453 K 731 K - -

Operating Income

-9.36 M -10.6 M -20.9 M -14.4 M -15.8 M -26.6 M -15.9 M -9.99 M -6.72 M -8.54 M -11.8 M -5.82 M -16.2 M -12.4 M -7.35 M -7.9 M -

Interest Expense

- - 30.6 K 15.1 K 15.8 K 10.7 K 7.3 K 5.79 K 216 K 4.12 K 76.7 K 4.03 K 17.5 K 656 K 332 K 33.9 K -

EBITDA

-9.36 M -10.6 M -20.9 M -14.4 M -15.7 M -26.6 M -15.8 M -9.97 M -6.65 M -8.47 M -11.6 M -5.79 M -16.1 M -12.4 M -7.27 M -7.86 M -

Operating Expenses

9.36 M 10.6 M 20.9 M 14.6 M 15.9 M 26.6 M 15.9 M 10 M 6.72 M 8.54 M 12.3 M 6.39 M 16.9 M 12.9 M 8.08 M 8.3 M -

General and Administrative Expenses

6.97 M 6.44 M 5.45 M 4.48 M 5.27 M 4.53 M 3.76 M 4.02 M 3.18 M 3.79 M 3.54 M 3.32 M 7.54 M 5.02 M 5.63 M 6.29 M -

All numbers in USD currency

Quarterly Income Statement Oragenics

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

732 K 4.3 M - 1.56 M 732 K 18.2 M 419 K 218 K 151 K 3.5 M 3.08 M 2.36 M 2.02 M 2.2 M 2.02 M 1.95 M 1.94 M 2 M 116 M 116 M 116 M 103 M 91.8 M 59.7 M 52.2 M 46.1 M 46.1 M 46.1 M 46.1 M 30.6 M 29.4 M 11.9 M 6.03 M 4.99 M 4.93 M 4.93 M 4.93 M 4.92 M 4.91 M 49.1 M 40.1 M 40 M 39.9 M 36.4 M 36.4 M 36.2 M 36.2 M 36.2 M 36.1 M 36.1 M 36 M 27.5 M 27.5 M 27.5 M 27.4 M 23.8 M 13.4 M 6.45 M 5.89 M 5.68 M 5.68 M 5.89 M

Net Income

-2.22 M -2.2 M - -3.07 M -2.27 M -2.22 M - -2.46 M -2.31 M -2.45 M - -2.01 M -3.05 M -2.84 M - -3.87 M -3.59 M -4.59 M - -4.38 M -3.82 M -5.22 M -4.41 M -4.5 M -12.3 M -5.19 M -3.6 M -3.84 M -4.81 M -3.33 M -2.76 M -2.76 M -2.28 M -2.12 M -1.46 M -2.07 M -1.22 M -1.98 M -2.67 M -1.96 M -313 K -2.06 M -2.22 M -1.86 M -6.34 M -1.29 M -1.22 M -1.03 M -1.9 M -1.64 M -3.08 M -9.33 M -2.07 M -1.59 M -1.99 M -2.56 M -6.93 M 1.62 M -1.94 M -1.81 M -2.37 M -1.56 M

Revenue

- - - - - - - - - - - 7.47 K 13.2 K 17 K - 86 K 30.4 K 15.1 K - - - - - - - - - - - - - - - - - - - - - - - - - - - 364 K 221 K 201 K 304 K 215 K 435 K 253 K 168 K 176 K 431 K 264 K 256 K 381 K 397 K 350 K 348 K 350 K

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 172 K - - - 196 K - 127 K 178 K 135 K - 140 K 81 K 112 K - 100 K 144 K 182 K - 216 K 18.8 K 255 K

Operating Income

-1.71 M -2.26 M - -3.12 M -1.71 M -2.03 M - -2.44 M -2.31 M -2.46 M - -2.09 M -3.11 M -2.9 M - -3.91 M -3.6 M -4.61 M - -4.39 M -3.84 M -5.24 M - -4.51 M -12.4 M -5.23 M - -3.92 M -4.9 M -3.39 M - -2.76 M -2.28 M -2.12 M - -1.92 M -1.4 M -1.99 M - -2.03 M -1.73 M -2.07 M - -1.87 M -6.34 M -1.3 M - -1.03 M -1.9 M -1.65 M - -9.33 M -2.08 M -1.74 M - -2.1 M -6.87 M -1.48 M - -1.71 M -2.3 M -1.52 M

Interest Expense

- - - - - - - - - 7.08 K - 14.2 K 843 3.35 K - 5.23 K 816 3.25 K - 7.05 K 1.03 K 2.57 K - 3.88 K 885 1.71 K - 2.5 K 733 1.3 K - 2.14 K 664 837 - 106 K 57.9 K 801 - 1.29 K 885 771 - 39.6 K 10 K 606 - 1.3 K 980 571 - 1.55 K 844 949 - 456 K 60.1 K 138 K - 96.7 K 67.7 K 43.8 K

EBITDA

-1.71 M -2.26 M - - - - - - - - - - -3.1 M -2.89 M - -3.87 M -3.59 M -4.6 M - -4.36 M -3.81 M -5.22 M - -4.47 M -12.3 M -5.22 M - -3.88 M -4.88 M -3.38 M - -2.75 M -2.27 M -2.11 M - -1.87 M -1.36 M -1.97 M - -1.97 M -1.7 M -2.06 M - -1.81 M -6.31 M -1.28 M - -1.01 M -1.89 M -1.64 M - -9.26 M -2.03 M -1.72 M - -2.04 M -6.83 M -1.46 M - -1.65 M -2.26 M -1.5 M

Operating Expenses

1.71 M 2.26 M - 3.12 M 1.71 M 2.03 M - 2.44 M 2.31 M 2.46 M - 2.1 M 3.12 M 2.92 M - 3.99 M 3.63 M 4.63 M - 4.39 M 3.84 M 5.24 M -4.55 M 4.51 M 12.4 M 5.23 M 3.66 M 3.92 M 4.9 M 3.39 M 2.82 M 2.76 M 2.28 M 2.12 M 1.41 M 1.92 M 1.4 M 1.99 M 2.71 M 2.03 M 1.73 M 2.07 M 2.2 M 1.87 M 6.34 M 1.37 M 1.36 M 1.16 M 2.08 M 1.78 M 3.43 M 9.47 M 2.16 M 1.85 M 2.01 M 2.2 M 7.01 M 1.66 M 2.06 M 1.93 M 2.32 M 1.77 M

General and Administrative Expenses

1.26 M 1.61 M - 2.19 M 1.26 M 1.68 M - 1.56 M 1.4 M 1.8 M - 1.33 M 1.12 M 1.25 M - 1.22 M 1.04 M 1.33 M - 847 K 1.37 M 1.98 M - 1.01 M 808 K 1.52 M - 853 K 1.03 M 980 K - 1.18 M 1.01 M 795 K - 925 K 791 K 865 K - 1.1 M 941 K 850 K - 762 K 732 K 815 K - 565 K 1.18 M 767 K - 2.56 M 1.52 M 1.1 M - 1.6 M 835 K 1.31 M - 1.36 M 1.69 M 1.36 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Oragenics OGEN
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Oragenics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
- -29.58 % $ 126 M usaUSA
Surface Oncology Surface Oncology
SURF
- - $ 59.7 M usaUSA
Sierra Oncology Sierra Oncology
SRRA
- -0.05 % $ 1.34 B canadaCanada
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.03 -6.33 % $ 11.6 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 4.24 -3.97 % $ 346 M usaUSA
Nektar Therapeutics Nektar Therapeutics
NKTR
$ 37.82 -0.01 % $ 638 M usaUSA
Vaccinex Vaccinex
VCNX
- -61.37 % $ 654 K usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 1.05 -3.24 % $ 242 M usaUSA
Jounce Therapeutics Jounce Therapeutics
JNCE
- - $ 98.4 M usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 7.0 -8.62 % $ 471 B britainBritain
Mersana Therapeutics Mersana Therapeutics
MRSN
- - $ 3.56 B usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Genmab A/S Genmab A/S
GMAB
$ 54.08 -3.08 % $ 3.5 B danmarkDanmark
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Timber Pharmaceuticals Timber Pharmaceuticals
TMBR
- - $ 717 K usaUSA
Immuron Limited Immuron Limited
IMRN
$ 0.9 2.27 % $ 208 M australiaAustralia
G1 Therapeutics G1 Therapeutics
GTHX
- - $ 370 M usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
BioVie BioVie
BIVI
$ 1.25 -3.85 % $ 9.06 M usaUSA
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Mustang Bio Mustang Bio
MBIO
$ 0.44 12.95 % $ 2.16 M usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
NexImmune NexImmune
NEXI
- 70.13 % $ 4.12 M usaUSA
Codexis Codexis
CDXS
$ 1.0 -9.91 % $ 87.1 M usaUSA
Theravance Biopharma Theravance Biopharma
TBPH
$ 17.03 0.03 % $ 857 M cayman-islandsCayman-islands
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.06 -3.72 % $ 192 M israelIsrael
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Sanofi Sanofi
SNY
$ 48.23 0.22 % $ 58.9 B franceFrance
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
LogicBio Therapeutics LogicBio Therapeutics
LOGC
- - $ 229 M usaUSA
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
$ 0.38 -5.06 % $ 4.68 B israelIsrael
89bio 89bio
ETNB
- - $ 1.55 B usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
- - $ 1.41 B canadaCanada
Gritstone Oncology Gritstone Oncology
GRTS
- 0.42 % $ 213 M usaUSA
Harpoon Therapeutics Harpoon Therapeutics
HARP
- - $ 763 M usaUSA
HOOKIPA Pharma HOOKIPA Pharma
HOOK
- -6.92 % $ 79.4 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Otonomy Otonomy
OTIC
- -1.96 % $ 4.68 M usaUSA